CLAIMS

1. Use of a composition comprising living CD4 immune cells comprising activated allogenic $CD4^+$ Th1 memory cells and an HIV antigen in the preparation of a medicament for the treatment or prevention of HIV in a patient, in which at least one intradermal dose of the composition is to be administered to the patient and in which at least one intravenous dose of the composition is to be administered to the patient.

2. Use according to Claim 1, in which an intravenous dose is to be administered within about 3 days of the or the last intradermal dose.

3. Use according to Claim 1, in which an intravenous dose is to be administered at about the same time as the or the last intradermal dose.

4. Use according to Claim 1, 2 or 3, in which at least two intradermal doses of the composition are to be administered to the patient.

5. Use according to Claim 4, in which two of the intradermal doses are to be administered at the same location.

6. Use according to Claim 4 or 5, in which the interval between intradermal doses is between about 3 days and about a week.

7. Use according to Claim 6, further comprising an additional two intradermal doses of the composition at a location different than the location of the first two intradermal doses.

8. Use according to any preceding claim, in which the or each intradermal dose of the composition when administered to the patient increases the titer of circulating $CD4^+$ Th1 memory cells that are resistant to HIV infection.

9. Use according to any preceding claim, in which the intravenous dose of the composition when administered to the patient expands and activates the $CD4^+$ Th1 memory cells in the patient.

10. Use according to any preceding claim, in which the patient is concurrently treated with highly active antiretroviral therapy (HAART).

11. Use according to any preceding claim, in which the composition comprises allogeneic activated $CD4^+$ T-cells.

12. Use according to any preceding claim, in which the latent viral load is reduced or eliminated in the patient.